BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24307515)

  • 1. inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
    Maesako Y; Izumi K; Okamori S; Takeoka K; Kishimori C; Okumura A; Honjo G; Akasaka T; Ohno H
    Int J Hematol; 2014 Feb; 99(2):202-7. PubMed ID: 24307515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
    Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
    Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.
    Lim JH; Jang S; Park CJ; Cho YU; Lee JH; Lee KH; Lee JO; Shin JY; Kim JI; Huh J; Seo EJ
    Cancer Genet; 2014; 207(1-2):40-5. PubMed ID: 24613277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
    Hergott CB; Dal Cin P; Hornick JL; Winer ES; Carrasco RD; Kim AS
    Am J Hematol; 2023 Feb; 98(2):365-367. PubMed ID: 33491794
    [No Abstract]   [Full Text] [Related]  

  • 5. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
    Ma Z; Hill DA; Collins MH; Morris SW; Sumegi J; Zhou M; Zuppan C; Bridge JA
    Genes Chromosomes Cancer; 2003 May; 37(1):98-105. PubMed ID: 12661011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).
    Colleoni GW; Bridge JA; Garicochea B; Liu J; Filippa DA; Ladanyi M
    Am J Pathol; 2000 Mar; 156(3):781-9. PubMed ID: 10702393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.
    Li J; Yin WH; Takeuchi K; Guan H; Huang YH; Chan JK
    Diagn Pathol; 2013 Sep; 8():147. PubMed ID: 24034896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
    Ma Z; Cools J; Marynen P; Cui X; Siebert R; Gesk S; Schlegelberger B; Peeters B; De Wolf-Peeters C; Wlodarska I; Morris SW
    Blood; 2000 Mar; 95(6):2144-9. PubMed ID: 10706887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma.
    Lee SE; Kang SY; Takeuchi K; Ko YH
    Hematol Oncol; 2014 Dec; 32(4):221-4. PubMed ID: 24470379
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
    Houssou B; Lamchahab M; Massi R; Oukkache B; Quessar A
    Bull Cancer; 2018 Jun; 105(6):552-555. PubMed ID: 29735159
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).
    Fonatsch C; Gudat H; Lengfelder E; Wandt H; Silling-Engelhardt G; Ludwig WD; Thiel E; Freund M; Bodenstein H; Schwieder G
    Leukemia; 1994 Aug; 8(8):1318-26. PubMed ID: 8057667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors.
    Patel AS; Murphy KM; Hawkins AL; Cohen JS; Long PP; Perlman EJ; Griffin CA
    Cancer Genet Cytogenet; 2007 Jul; 176(2):107-14. PubMed ID: 17656252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
    Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute myelomonocytic leukemia with inv (16) (p13 q22) disappeared abnormal karyotype during complete remission].
    Tsushima Y; Yukita T; Mikami T; Takami H; Aihara M; Kawamura S; Yoshida Y; Chiba Y
    Rinsho Ketsueki; 1989 Dec; 30(12):2178-82. PubMed ID: 2621800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidental identification of inv(16)(p13.1q22)/
    Quesada AE; Luthra R; Jabbour E; Patel KP; Khoury JD; Tang Z; Alvarez H; Mallampati S; Garcia-Manero G; Montalban-Bravo G; Medeiros LJ; Kanagal-Shamanna R
    Cold Spring Harb Mol Case Stud; 2021 Jun; 7(3):. PubMed ID: 34117074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma.
    Wlodarska I; De Wolf-Peeters C; Falini B; Verhoef G; Morris SW; Hagemeijer A; Van den Berghe H
    Blood; 1998 Oct; 92(8):2688-95. PubMed ID: 9763551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Shao H; Yang Q; Wu C; Cen J; Chen S; Pan J
    Ann Hematol; 2017 Dec; 96(12):2127-2129. PubMed ID: 28840298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.